Cargando…

Chronic Antagonism of the Mineralocorticoid Receptor Ameliorates Hypertension and End Organ Damage in a Rodent Model of Salt-Sensitive Hypertension

We investigated the effects of chronic mineralocorticoid receptor blockade with eplerenone on the development and progression of hypertension and end organ damage in Dahl salt-sensitive rats. Eplerenone significantly attenuated the progressive rise in systolic blood pressure (SBP) (204 ± 3 vs. 179±3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaoyan, Crook, Martin F, Sharif-Rodriguez, Wanda, Zhu, Yonghua, Ruben, Zadok, Pan, Yi, Urosevic-Price, Olga, Wang, Li, Flattery, Amy M, Forrest, Gail, Szeto, Daphne, Zhao, Huawei, Roy, Sophie, Forrest, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3231850/ https://www.ncbi.nlm.nih.gov/pubmed/21950654 http://dx.doi.org/10.3109/10641963.2011.566956

Ejemplares similares

Mineralocorticoid hypertension
por: Gupta, Vishal
Publicado: (2011)

GLUCOCORTICOID-INDUCED HYPERTENSION AND CARDIAC INJURY: EFFECTS OF MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ANTAGONISM
por: HATTORI, TAKUYA, et al.
Publicado: (2013)

The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension
por: Shibata, Shigeru, et al.
Publicado: (2011)

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
por: Clemmer, John S., et al.
Publicado: (2019)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
por: Boughton, Charlotte, et al.
Publicado: (2018)

Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2021)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Upregulation of Mineralocorticoid Receptor Contributes to Development of Salt-Sensitive Hypertension after Ischemia–Reperfusion Injury in Rats
por: Matsumoto, Takumi, et al.
Publicado: (2022)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Urinary Exosomes and Their Cargo: Potential Biomarkers for Mineralocorticoid Arterial Hypertension?
por: Barros, Eric R., et al.
Publicado: (2017)

The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
por: Baudrand, Rene, et al.
Publicado: (2018)

Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension
por: Menon, Divya P., et al.
Publicado: (2021)

Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV
por: Srinivasa, Suman, et al.
Publicado: (2021)

Caffeine intake antagonizes salt sensitive hypertension through improvement of renal sodium handling
por: Yu, Hao, et al.
Publicado: (2016)

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?
por: Mortensen, Line Aas, et al.
Publicado: (2017)

Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage
por: Fels, Benedikt, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!
por: Maiolino, Giuseppe, et al.
Publicado: (2015)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
por: Crompton, Michael, et al.
Publicado: (2023)

New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension
por: Narayan, Hafid, et al.
Publicado: (2016)

PMON87 A Case of Mineralocorticoid Induced Hypertension Secondary to Cushing's Syndrome
por: Abideen, Zain U, et al.
Publicado: (2022)

Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research
por: Mamazhakypov, Argen, et al.
Publicado: (2023)

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension
por: Burke, Sandra L., et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonism Attenuates Multiple Organ Failure after Renal Ischemia and Reperfusion in Mice
por: Park, Eun Jung, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction
por: Schena, Elisa, et al.
Publicado: (2023)

Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
por: Shi, Luo, et al.
Publicado: (2019)

Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension
por: Mansur, Arian, et al.
Publicado: (2023)

Dietary Salt Intake and Hypertension
por: Ha, Sung Kyu
Publicado: (2014)

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism
por: Eudy, Rena J, et al.
Publicado: (2011)

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury
por: Luther, James M., et al.
Publicado: (2012)

The Effect of Mineralocorticoid and Glucocorticoid Receptor Antagonism on Autobiographical Memory Recall and Amygdala Response to Implicit Emotional Stimuli
por: Young, Kymberly D., et al.
Publicado: (2016)

Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve
por: Ibarrola, Jaime, et al.
Publicado: (2020)

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis
por: Takahashi, S, et al.
Publicado: (2016)

Preexisting hypertension and pregnancy-induced hypertension reveal molecular differences in placental proteome in rodents
por: Mary, Sheon, et al.
Publicado: (2021)

GLUCOCORTICOIDS ACTIVATE CARDIAC MINERALOCORTICOID RECEPTORS IN ADRENALECTOMIZED DAHL SALT-SENSITIVE RATS
por: OHTAKE, MASAFUMI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tkkk9fo0pkev6mq1j0lennk9t8